NCT02477826

GPTKB entity

Statements (23)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:ageRange 18 years and older
gptkbp:clinicalTrialPhase Phase 3
gptkbp:clinicalTrialsGovURL https://clinicaltrials.gov/ct2/show/NCT02477826
gptkbp:conditionStudied gptkb:Non-Small_Cell_Lung_Cancer
gptkbp:enrollment 1274
gptkbp:gender All
https://www.w3.org/2000/01/rdf-schema#label NCT02477826
gptkbp:intervention gptkb:Placebo
gptkb:Pembrolizumab
gptkbp:location gptkb:Europe
gptkb:United_States
gptkbp:officialName A Phase 3 Study of Pembrolizumab (MK-3475) as Adjuvant Therapy in Participants With Resected Stage IB (T ≥4 cm), II or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-091)
gptkbp:primaryCompletionDate September 2022
gptkbp:primaryOutcomeMeasure Disease-Free Survival (DFS)
gptkbp:recognizedBy KEYNOTE-091
gptkbp:secondaryOutcomeMeasure Overall Survival (OS)
gptkbp:sponsor gptkb:Merck_Sharp_&_Dohme_LLC
gptkbp:startDate June 2015
gptkbp:status Completed
gptkbp:studyType Interventional
gptkbp:bfsParent gptkb:CheckMate_227
gptkbp:bfsLayer 7